...
机译:三周联合化疗联合S-1和顺铂作为一线治疗晚期胃癌:159例患者的回顾性研究
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea;
Department of Oncology, Asan Medical Center, Unive;
Stomach neoplasms; S-1; Cisplatin; Chemotherapy; Prognosis;
机译:S-1和顺铂三线联合化疗作为晚期胃癌患者的一线治疗:159例患者的回顾性研究
机译:顺铂/ S-1联合治疗晚期胃或胃食管腺癌患者:在一线晚期胃癌研究中与顺铂/ 5-氟尿嘧啶相比的非劣效性和安全性分析结果
机译:S-1加顺铂联合化疗作为一线治疗晚期胃癌患者的远期疗效和预后因素
机译:S-1 / CDDP / Lentinan组合化疗,可管理的胃癌无法操作
机译:吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
机译:两周一次奥沙利铂联合S-1联合化疗作为中国转移性或晚期胃癌患者一线治疗的II期研究
机译:三周组合化疗用S-1和顺铂作为晚期胃癌患者的一线治疗:具有159名患者的回顾性研究